RCUS (Arcus Biosciences) Float Percentage Of Total Shares Outstanding: 60.78% (As of Jun. 28, 2026)


RCUS Arcus Biosciences Inc RCUS
46 GF Score
Price $31.00
GF Value $13.76
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arcus Biosciences Float Percentage Of Total Shares Outstanding?

Arcus Biosciences RCUS +2.48% 46 Float Percentage Of Total Shares Outstanding is 60.78% as of Jun. 28, 2026. GuruFocus rates RCUS with a GF Score™ of 46/100 and a GF Value™ of $13.76 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Arcus Biosciences's float shares is 76.44 Mil. Arcus Biosciences's total shares outstanding is 125.77 Mil. Arcus Biosciences's float percentage of total shares outstanding is 60.78%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Arcus Biosciences's Insider Ownership is 2.96%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Arcus Biosciences's Institutional Ownership is 101.16%.

RCUS
46GF Score
Arcus Biosciences Inc RCUS
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcus Biosciences Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Arcus Biosciences's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=76.44/125.77
=60.78%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 60.78% mean?
Arcus Biosciences (RCUS) has a Float Percentage Of Total Shares Outstanding of 60.78% as of Jun. 28, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Arcus Biosciences and its competitors.
Is Arcus Biosciences' Float Percentage Of Total Shares Outstanding too high?
Arcus Biosciences' current Float Percentage Of Total Shares Outstanding is 60.78%. Overall, Arcus Biosciences has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcus Biosciences' Float Percentage Of Total Shares Outstanding compare to TNGX and DYN?
Arcus Biosciences' Float Percentage Of Total Shares Outstanding of 60.78% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Arcus Biosciences and its competitors. Arcus Biosciences's current Float Percentage Of Total Shares Outstanding is 60.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcus Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Arcus Biosciences (RCUS) is currently considered Significantly Overvalued. The stock's GF Value™ is $13.76, compared to a current price of $31.00 — trading 125.3% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 60.78%. Arcus Biosciences' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Arcus Biosciences (RCUS), the current Float Percentage Of Total Shares Outstanding is 60.78% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcus Biosciences (RCUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arcus Biosciences stock appears to be overvalued. The current stock price of $31.00 is trading 125.3% above its estimated GF Value™ of $13.76. GuruFocus considers Arcus Biosciences to be Significantly Overvalued.

Key valuation signals for RCUS:

  • Float Percentage Of Total Shares Outstanding: 60.78%
  • GF Value™: $13.76 vs. price of $31.00 (125.3% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the RCUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcus Biosciences Business Description

Address 3928 Point Eden Way, Hayward, CA, USA, 94545
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
46GF Score

Get the complete analysis for RCUS

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.00
Price
$13.76
GF Value